Following the science to improve patient outcomes
What will make the biggest difference?
Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.
Whether you’re a bench scientist, whether you’re in commercial, whether you’re in development, it’s taking great ideas, innovative science and translating them into medicines that are going to make a transformational difference to patients. That’s what drives us, and that’s what science can do.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Respiratory (as at 27 July 2017)
I have a passion to develop medicines that help patients who don’t otherwise have options. This is very rewarding and motivating for me, and keeps me focused on seeking the evidence, and collaborating with other investigators who share a similar vision to pursue the science that benefits all of mankind.Roland Kolbeck, PhD, VP, R&D Respiratory, Inflammation and Autoimmunity (RIA)
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Commitment to science
Our commitment to science is reflected in our track record of publications. View recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
AstraZeneca to present data on next generation of biologics at European Respiratory Society International Congress 2017
Our focus on unmet medical needs
Improving patient outcomes with tailored therapies, devices, and support tools
Global burden of respiratory diseases
Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)
Inhaled therapies and novel combinations
Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum
Targeted biologic therapies
Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies
AstraZeneca’s work environment is dynamic and fosters innovation. We believe where there’s energy, there’s fulfillment, and with jobs from Cambridge, UK to Shanghai, China, we’ve got the role for you.
Veeva ID: Z4-4823
Date of prep: 22/05/2017
Date of expiry: 22/05/2018